Navigation Links
Gene mutation may lead to treatment for liver cancer
Date:7/8/2014

Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature.

A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH mutations to be among the most common genetic differences seen in patients with iCCA, but how they contribute to cancer development was unknown going into the current effort.

iCCA strikes bile ducts, tube-like structures in the liver that carry bile, which is required for the digestion of food. With so much still unknown about the disease, there is no first-line, standard of care and no successful therapies.

"iCCA is resistant to standard treatments like chemotherapy and radiation," said Josep Maria Llovet, MD, Director of the Liver Cancer Program, Division of Medicine, Icahn School of Medicine at Mount Sinai, and contributing author. "Understanding the molecular mechanism of the disease is the key to finding a treatment that works."

Dr. Llovet and colleagues demonstrated that the expression of mutant IDH in the adult liver of genetically engineered mice impairs liver cell development and liver regeneration a process in which the liver responds to injury and increases the number of cells to form a tumor. Moreover, mutant IDH were found to work with activated KRAS, a gene essential in cancer development, causing the development of premalignant lesions and a progression to metastatic iCCA.

"Our findings provide novel insights into the development iCCA and offers a possible treatment option for patients suffering from this fatal disease," said Dr. Llovet.

By pinpointing one pathway of iCCA, this study opens up a new line of investigation to identify biomarkers of the disease. Already, Phase 1 clinical trials are being conducted with specific IDH1/2 mutations. The hope is that results of these and future studies can help doctors make life-saving decisions for their patients.


'/>"/>

Contact: Lucia Lee
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Researchers identify mitochondrial mutation linked to congenital myasthenic syndrome
2. Severe scoliosis linked to rare mutations
3. Newly identified brain cancer mutation will aid drug development
4. Gene mutation found for aggressive form of pancreatic cancer
5. Univ. of MD researchers identify fat-storage gene mutation that may increase diabetes risk
6. Small mutation changes brain freeze to hot foot
7. Scripps Florida scientists find connection between gene mutation, key symptoms of autism
8. Virus-fighting genes linked to mutations in cancer
9. Key genetic mutations could be new hope for adrenocortical tumor patients
10. Erasing a genetic mutation
11. Genetic mutations warn of skin cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... announced today that the Company has concluded an agreement ... right for a 90-day period to acquire units of ... of approximately USD 3.7 million.  Concurrently ... with Tamarack under which Tamarack will seek regulatory approvals ...
(Date:11/30/2016)... -- GenomOncology today announced the appointment of Joshua F. Coleman ... Dr. Coleman will oversee clinical content development and curation ... GenomOncology software suite empowers molecular pathologists with a seamless workflow ... support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... SEATTLE , Nov. 30, 2016  The ... Allen Cell Collection: the first publicly available collection ... stem cells that target key cellular structures with ... Medical Research, these powerful tools are a crucial ... cells to better understand what makes human cells ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
Breaking Biology Technology: